Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B cell lymphoma and leukemia

CD47, a ubiquitously expressed innate immune checkpoint receptor that serves as a universal “don’t eat me” signal of phagocytosis, is often up-regulated by hematological and solid cancers to evade immune surveillance. Development of CD47-targeted modalities is hindered by the ubiquitous expression o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Cancer Ther
Autors principals: Buatois, Vanessa, Johnson, Zoë, Pires, Susana Salgado, Papaioannou, Anne, Hatterer, Eric, Chauchet, Xavier, Richard, Françoise, Barba, Leticia, Daubeuf, Bruno, Cons, Laura, Broyer, Lucile, D’Asaro, Matilde, Matthes, Thomas, LeGallou, Simon, Fest, Thierry, Tarte, Karin, Hinojosa, Robert K. Clarke, Ferrer, Eulàlia Genescà, Ribera, José María, Dey, Aditi, Bailey, Katharine, Fielding, Adele K., Eissenberg, Linda, Ritchey, Julie, Rettig, Michael, DiPersio, John F., Kosco-Vilbois, Marie H., Masternak, Krzysztof, Fischer, Nicolas, Shang, Limin, Ferlin, Walter G.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6072583/
https://ncbi.nlm.nih.gov/pubmed/29743205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-1095
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars